Project Grant R01CA301410
Award Date
7/10/25
Completion Date
4/30/30
Dollars Obligated
$656K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $2,489,032 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The 5-year award, effective August 1, 2025, will support three highly integrated research projects focused on determining the roles, regulation, and underlying mechanisms of lipid metabolism in ferroptosis, a form of iron-dependent cell death, and exploring novel cancer therapeutic approaches based on these...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $730,398 to the Sloan-Kettering Institute for Cancer Research to investigate the relationship between leptomeningeal cancer cell growth and inflammatory signaling in the leptomeningeal space. The research aims to mechanistically dissect the CXCL1-CXCR2 signaling axis within the leptomeningeal space, identify cancer cell signals that provoke leptomeningeal CXCL1 generation, and...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in both normal prostate cell function and prostate cancer development. The $564,543 award, effective March 1, 2025 through February 28, 2030, will enable the research team to determine the factors that mediate the switch between AR's normal, growth-suppressive...
This Project Grant award of $683,979.00, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Weill Medical College of Cornell University to define the molecular mechanisms underlying distinct prostate cancer subtypes and their progression to treatment-resistant disease. The research aims to elucidate how early genetic alterations, particularly mutations in the SPOP gene, impact prostate cancer lineage fidelity and shape...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
This Project Grant award of $148,050, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research to study the role of the APOBEC3 (A3) family of enzymes in driving genomic instability and mutagenesis in lung cancer. The primary objectives are to: 1) Identify the specific A3 family members responsible for lung cancer mutagenesis, 2) Evaluate potential surrogate measures of A3 mutagenesis, and 3) Investigate how A3 enzymes regulate endogenous...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
The National Cancer Institute (NCI) awarded a $2,679,816 Project Grant (CFDA 93.396 Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai. The 5-year grant, effective August 1, 2025, will support an integrated research program focused on understanding the role of mutant p53 proteins in tumor progression, invasion, and metastasis. The program consists of four interrelated projects that will use systematic studies, molecular mechanisms, and transcriptional regulation approaches...
This $2,561,215 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by Weill Medical College of Cornell University to investigate the epigenetic and immunological basis of diffuse large B-cell lymphoma (DLBCL). The project aims to: 1) Understand how chromatin and immune signaling pathways regulate key germinal center B-cell fate decisions in DLBCL; 2) Characterize how DLBCL subtypes defined by their chromatin landscapes interact with...
This Project Grant award of $108,512 from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program supports research at Weill Medical College of Cornell University to investigate the chromatin landscape of alternative lengthening of telomeres (ALT) in cancer cells. The award, effective March 1, 2025 through February 28, 2029, will enable the researcher to: 1) use a base editing screen to identify ATRX domains and functions that suppress ALT, and 2) study the effect of...